A new ‘liquid’ option for lung cancer testing
RUTHERFORD, N.J. & LOS ANGELES—Cancer Genetics Inc. (CGI) kicked off May with the validation and commercial launch of its next-generation sequencing assay Liquid::Lung-cfDNA, which detects lung tumor-derived cell-free DNA (cfDNA) obtained from the plasma fraction of blood. The test makes it possible to analyze frequently mutated single nucleotide variants and short indels in 11 genes that have significant clinical relevance in non-small cell lung cancer. The assay is based on ThermoFisher Scientific’s Oncomine Lung cfDNA assay and runs on the Ion S5 XL sequencing system. In addition, CGI’s assay includes Ion AmpliSeq library preparation technology and is compatible with FFPE samples.
“By offering a focused liquid biopsy panel that provides information for known molecular pathways and has significant clinical evidence, we are enabling a new era in precision medicine for our customers and their patients, leading to improvements in standard of care in the future,” said Panna Sharma, president and CEO of CGI.